See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Baseball
Natural Disasters
Social Media
Tariffs
Trade War
Donald Trump
Artificial Intelligence
Boxing
Tennis
Floods
Trade
Golf
Published • loading... • Updated

Higher-Dose Ocrelizumab Shows No Added Benefit vs Approved Dose in MS

Summary by ajmc.com
The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow disability progression for patients with multiple sclerosis (MS).
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All
Left
Center
Right
ajmc.comajmc.com

Higher-Dose Ocrelizumab Shows No Added Benefit vs Approved Dose in MS

The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow disability progression for patients with multiple sclerosis (MS).

Read Full Article
Clinical Trials ArenaClinical Trials Arena

Roche’s high-dose Ocrevus fails primary endpoint in MS trial

Higher doses of the company’s multiple sclerosis drug failed to show additional benefit in slowing rates of disability progression.The post Roche’s high-dose Ocrevus fails primary endpoint in MS trial appeared first on Clinical Trials Arena.

Read Full Article
neurologylive.comneurologylive.com

Genentech Reports High-Dose Ocrelizumab Fails to Show Additional Benefit in Relapsing MS

The company's phase 3 MUSETTE trial reported that an increased ocrelizumab dose did not further slow disability progression but reinforced the efficacy of the approved 600 mg dose.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

neurologylive.com broke the news in on Wednesday, April 2, 2025.
Sources are mostly out of (0)

Similar News Topics

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal